Pooled prevalence, risk factors and barriers to care for hepatitis C virus (HCV) in adults with serious mental illness (SMI): an updated systematic review and meta-analysis – protocol Authors: Saba Maryam, Mehreen Noor, Afifa Kulsoom Published: 2026 ABSTRACT Abstract AbstractIntroductionThe hepatitis C virus (HCV) is a significant healthcare burden across the globe and is a major cause of liver malignancies. However, patients with serious mental illness (SMI) living with HCV are disproportionately affected and underserved within the current care framework. A previous meta-analysis on this topic yielded a prevalence of 8%, which is considerably higher than that observed in the broader population. Since the original review was published in early 2022, an update is required to incorporate data published during and after the COVID-19 pandemic and to evaluate its effect on overall prevalence and care.MethodologyThis systematic review and meta-analysis will replicate the methodology of the original review. To ensure a thorough investigation, a systematic search strategy will be implemented across PubMed, Google Scholar, Scopus, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase and Web of Science to include studies published from 2 July 2020 to 22 June 2026. The review will include prospective observational and retrospective cross-sectional studies conducted among adults aged over 18 years with a verified SMI diagnosis and laboratory-confirmed HCV status. A dual-reviewer protocol will be employed to evaluate all retrieved titles, abstracts and full-text manuscripts to ensure unbiased selection. Any disagreements will be adjudicated by a third senior investigator. Methodological rigour will be assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Prevalence Studies Quality Assessment Tool for Systematic Reviews of Observational Studies. This validated instrument will ensure transparency and standardised quality assessment and will be supplemented by a customised 3-point global assessment. A Generalised Linear Mixed Model (GLMM) with a logit transformation will be used for the meta-analytical synthesis to effectively account for expected heterogeneity and extreme proportions, while the degree of inconsistency across studies will be quantified using the I2 statistic.Ethics and disseminationFormal ethical clearance is not required for this study, as it relies entirely on the synthesis of secondary data from published articles.PROSPERO registration numberCRD420261331799.Keywords: GASTROENTEROLOGY, PSYCHIATRY, Schizophrenia & psychotic disorders, PUBLIC HEALTH STRENGTHS AND LIMITATIONS OF THIS STUDY Studies are restricted to populations with a verified serious mental illness diagnosis, explicitly excluding primary homelessness and substance-use disorder cohorts, to minimise ascertainment bias in prevalence Studies are restricted to populations with a verified serious mental illness diagnosis, explicitly excluding primary homelessness and substance-use disorder cohorts, to minimise ascertainment bias in prevalence The eligibility criteria are designed to capture both hepatitis C virus prevalence data and linkage-to-care outcomes, enabling a dual-domain synthesis within a single search and extraction framework. The eligibility criteria are designed to capture both hepatitis C virus prevalence data and linkage-to-care outcomes, enabling a dual-domain synthesis within a single search and extraction framework. A Generalised Linear Mixed-effects Model with a logit link function and I² heterogeneity quantification will be employed to handle expected clinical and methodological diversity across study settings. A Generalised Linear Mixed-effects Model with a logit link function and I² heterogeneity quantification will be employed to handle expected clinical and methodological diversity across study settings. Restriction to English-language publications may under-represent research from non-Anglophone regions (eg, Latin American, Eastern European and East Asian populations), and excluded studies will be tracked by geographic origin to transparently document this limitation. Restriction to English-language publications may under-represent research from non-Anglophone regions (eg, Latin American, Eastern European and East Asian populations), and excluded studies will be tracked by geographic origin to transparently document this limitation. Introduction As a critical threat to global health, HCV is a primary driver of persistent hepatic inflammation, which often culminates in liver scarring and malignant transformations.1 Despite major advances in antiviral therapy, particularly the development of potent direct-acting antiviral (DAA) agents, HCV continues to affect millions of people worldwide.2 Global estimates suggest that approximately 1% of the adult population is infected with HCV, representing a high burden of morbidity and mortality associated with liver-related complications and extrahepatic manifestations.1 Effective strategies for screening, diagnosis and treatment have significantly improved outcomes; however, certain vulnerable populations remain disproportionately affected and underserved within HCV prevention and care frameworks.1 Among these high-risk populations are individuals living with serious mental illness (SMI), including disorders such as schizophrenia, bipolar disorder and major depressive disorder with psychotic features.3 People with SMI often experience a combination of biological, behavioural and social vulnerabilities that increase their susceptibility to infectious diseases, including blood-borne viruses such as HCV.3 Multiple studies have demonstrated that the prevalence of HCV infection among individuals with SMI is much higher than that of the general population.3 4 A systematic review and meta-analysis reported a pooled HCV seroprevalence of approximately 8%, which is several times higher than the global prevalence observed in the general population, reinforcing the need for targeted screening and prevention strategies in psychiatric populations.3 Recent meta-analytic evidence suggests geographic variation in infection rates: in Western regions such as North America and Europe, the burden of blood-borne viruses among those with SMI significantly exceeds that of the general public. Conversely, in high-prevalence regions such as Asia, infection rates within the SMI population appear on par with the broader community.3 The HCV burden within the SMI cohort was most pronounced in North America, with a prevalence of 17.4% (95% CI 13.2 to 22.6). In contrast, European and Asian regions reported lower figures, estimated at 4.9% (95% CI 3.0 to 7.9) and 4.4% (95% CI 2.8 to 6.9), respectively.3 Psychiatric inpatients and outpatients have a reported HCV prevalence approaching 20%, which is much greater than in the general population.5 The increased burden of HCV among individuals with SMI can be attributed to a complex interplay of risk factors.3 4 Behavioural risk factors, particularly injection drug use (IDU), represent one of the strongest contributors to HCV transmission in this population.6 Dual disorders (DDs) are defined as the co-occurrence of substance use disorders or behavioural addictions with another mental disorder.7 These disorders are linked to numerous medical and mental conditions. Substance misuse disorders affect between 30% and 50% of individuals with major mental illnesses, which can result in risky behaviours that promote viral transmission and the risk of infection with HCV.3 In Europe, the prevalence of HCV is much higher, ranging from 14% to 84% among drug users especially those with a history of injecting drug use.8 Compared with the general population, these cohorts have less access to healthcare, placing them at a higher risk of death and a significant public health issue.9 Substance use disorders frequently co-occur with psychiatric illnesses, and studies have shown that the lifetime prevalence of IDU among people with SMI can range from 16% to 22%. Such behaviours significantly elevate the risk of blood-borne infections through exposure to contaminated needles or equipment.3 4 In addition to substance use, individuals with SMI tend to have social and structural vulnerabilities that make them more susceptible to HCV infection. These include homelessness, imprisonment, poverty and limited access to healthcare services.3 4 Higher rates of incarceration among people with SMI are particularly relevant because correctional settings have historically reported an elevated prevalence of HCV infection due to concentrated high-risk behaviours and limited harm-reduction services.10 Furthermore, cognitive impairment, impaired judgement and social marginalisation may contribute to risky behaviours and reduced engagement in preventive healthcare services.3 Among individuals with SMI, sex differences in the epidemiology of HCV have also been reported. A previous meta-analysis indicated that the prevalence of HCV may be higher in men than in women because of differences in behavioural risk profiles and substance use patterns.3 6 Despite the high prevalence of HCV infection in the SMI population, individuals with SMI remain significantly underserved within HCV screening and treatment programmes.11 There are various obstacles to diagnosis and care access, such as stigma related to mental illness and viral hepatitis, ineffective healthcare systems, insufficient integration of psychiatric and infectious disease care and low awareness of healthcare providers on the topic of HCV among psychiatric populations.12 Routine blood-borne virus screening is not always adopted in most mental health settings because of doubts about clinical accountability, paucity of resources or absence of referral channels.13 Moreover, individuals with SMI can also face challenges across the HCV care cascade, such as decreased testing rates, delayed diagnosis, low rates of linkage to specialist care and low treatment initiation rates.14 Although modern antiviral therapies offer cure rates exceeding 95%, disparities in healthcare access and engagement continue to limit treatment uptake among vulnerable groups.15 Addressing these gaps is crucial for achieving the milestone set by the WHO of elimination of viral hepatitis as a threat to public health by 2030.16 17 Moreover, few epidemiological studies have examined hospitalised patients with persistent mental illness and DDs, although the prevalence of HCV is high in patients with psychiatric and/or substance addiction disorders.3 Figure 1 illustrates the conceptual framework explaining the pathways between serious mental illness, risk factors and barriers to HCV linkage to care. Conceptual logic model illustrating the pathways between serious mental illness, risk drivers and barriers to HCV care linkage. HCV, hepatitis C virus; SMI, serious mental illness. Since the original review was published in early 2022, the COVID-19 pandemic has greatly affected vulnerable individuals and healthcare systems across the globe. The pandemic has potentially impacted all of these domains, particularly HCV prevalence, risk factors and access to medical care, through disruptions to routine medical services, changes in resource allocation and changes in social behaviours. Thus, it is essential to have an updated synthesis that reflects these recent epidemiological changes and their consequences for this poorly studied population. This study will determine the prevalence of HCV infection in patients with SMI and risk factors linked with the infection. This study will also find out barriers towards screening, diagnosis and treatment. This current review aims to provide a broader view of HCV load among adults with diagnosed SMI through data from previously published studies. This review also aims to direct efforts to increase screening, access to treatment and integrated model of care for this high risk population. Objectives Primary objective To quantify the most recent combined prevalence of HCV infection among adults diagnosed with SMI. Secondary objectives To identify and analyse recent trends in barriers to care and treatment uptake among the SMI population. To identify and analyse recent trends in barriers to care and treatment uptake among the SMI population. To incorporate data published during and following the COVID-19 pandemic to understand its impact on HCV prevalence and care. To incorporate data published during and following the COVID-19 pandemic to understand its impact on HCV prevalence and care. To identify risk factors associated with HCV infection in this population. To identify risk factors associated with HCV infection in this population. To evaluate screening consent rates and the effectiveness of linkage to care for patients following a positive diagnosis. To evaluate screening consent rates and the effectiveness of linkage to care for patients following a positive diagnosis. Methods and analysis The structural framework of this protocol adheres to the standards established by the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement for systematic review design.18 The predefined methodology for this review has been officially archived with PROSPERO (the International Prospective Register of Systematic Reviews) on 4 March 2026 under registration no. CRD420261331799. Eligibility criteria (PICO) The review will include studies meeting the following criteria: The Population (P) will be adults (age >18 years) with a verified diagnosis of SMI (schizophrenia, bipolar disorder or major depressive disorder with functional impairment). The Intervention/Exposure (I) will be HCV infection confirmed via laboratory-based serology (HCV-Ab) or validated International Classification of Diseases (ICD) coded registry data. The Comparator (C) will be the general population controls or non-SMI psychiatric cohorts (where available). The study design will be prospective observational and retrospective cross-sectional studies. The setting will be inpatient, outpatient and community mental health settings selected. Only articles published in the English language will be included. Although a thorough search across several databases will attempt to reduce language bias, it is possible that some geographical regions such as Latin America, Eastern Europe or East Asia may be under-represented because relevant studies are published in other languages. To assess the potential impact of language bias, the number and geographic origin (when identifiable through English abstracts) of studies excluded solely because of language restrictions will be explicitly tracked and reported. Figure 2 shows the PICO framework that will be used in the study. PICO framework defining the population, exposure, comparator and outcomes for study eligibility. HCV, hepatitis C virus; SMI, serious mental illness; MDD, Major depressive disorder; ICD-coded registries, International Classification of Diseases coded registries Exclusion criteria Studies in which the primary inclusion criterion is homelessness or substance use disorder, that lack a clear denominator for the screened population, that report self-reported HCV status without clinical or registry verification or that represent redundant datasets or sub-analyses of previously published systematic reviews will be excluded. Search strategy and evidence selection To ensure a thorough investigation, a systematic search strategy will be implemented across PubMed, Google Scholar, CINAHL, Scopus, Embase and Web of Science for studies published from 2 July 2020 to 22 June 2026. The search strategy will use Boolean operators to cross-reference HCV-related terms with SMI-related terms. Table 1 shows the detailed search strategies for all databases. Table 1Detailed search strategy and strings for all databasesDatabaseSearch stringPubMed(((“Hepatitis C”(Mesh])OR “Hepatitis C, Chronic”(Mesh])OR “HCV”(tw])OR “Hepatitis C virus”(tw])OR “HCV seroprevalence”(tw])OR “HCV prevalence”(tw))) AND ((“Mentally Ill Persons”(Mesh])OR “Mental Disorders”(Mesh])OR “Schizophrenia Spectrum and Other Psychotic Disorders”(Mesh])OR “Bipolar Disorder”(Mesh])OR “Depressive Disorder, Major”(Mesh])OR “Serious Mental Illness”(tw])OR “Severe Mental Illness”(tw])OR “SMI”(tw])OR “Psychiatric patients”(tw])OR “Chronic mental illness”(tw))))Google Scholar(“HCV” OR “Hepatitis C” OR “Hep C”) AND (“SMI” OR “serious mental illness” OR “schizophrenia” OR “bipolar” OR “major depression”) AND (“prevalence” OR “incidence” OR “barriers” OR “treatment”)Embase('hepatitis C’/exp OR 'hepatitis C virus’/exp OR 'hcv’:ti,ab OR 'hcv prevalence’:ti,ab OR 'hcv seroprevalence’:ti,ab) AND (’severe mental disorder’/exp OR ’serious mental illness’:ti,ab OR ’severe mental illness’:ti,ab OR ’schizophrenia’/exp OR 'bipolar disorder’/exp OR 'major depression’/exp OR 'psychiatric patient’/exp)ScopusTITLE-ABS-KEY ((“Hepatitis C” OR “HCV” OR “HCV prevalence” OR “HCV seroprevalence”) AND (“serious mental illness” OR “severe mental illness” OR “SMI” OR “schizophrenia” OR “bipolar disorder” OR “major depression” OR “psychiatric patient”))CINAHL((MH "Hepatitis C+") OR TX HCV OR TX "HCV prevalence") AND ((MH "Mental Disorders+") OR TX "serious mental illness" OR TX "severe mental illness" OR TX SMI OR TX "psychiatric patients")Web of ScienceTS=((“Hepatitis C” OR “HCV” OR “HCV prevalence” OR “HCV seroprevalence”) AND (“serious mental illness” OR “severe mental illness” OR “SMI” OR “schizophrenia” OR “bipolar disorder” OR “major depression”))Abbreviation: CINAHL,Cumulative Index to Nursing and Allied Health Literature Detailed search strategy and strings for all databases Abbreviation: CINAHL,Cumulative Index to Nursing and Allied Health Literature Study selection Literature search results will be exported to the reference management software (Rayyan).19 To ensure unbiased selection, a dual-reviewer protocol will be employed to evaluate all retrieved titles, abstracts, and full-text manuscripts, with any disagreements adjudicated by a third senior investigator. The PRISMA-P flow diagram for the identification, screening, and inclusion of studies is shown in figure 3. PRISMA-P flow diagram template for the identification, screening and inclusion of studies. HCV, hepatitis C virus; PRISMA-P, Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols; SMI, serious mental illness; CINAHL, Cumulative Index to Nursing and Allied Health Literature; MDD, Major depressive disorder; TBD, To be decided Data extraction The data extraction process will capture study-level descriptors, including authorship and publication year, alongside geographic location, clinical setting, and patient-specific demographics, including age, sex and specific SMI diagnosis. HCV metrics will include the number of patients screened, the number testing positive for HCV, the screening method, as well as secondary outcomes, such as risk factors and linkage-to-care rates. Risk of bias (quality assessment) The methodological integrity of the shortlisted observational studies will be evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Prevalence Studies, in accordance with established guidelines.20 This validated instrument is designed for prevalence meta-analyses and will ensure transparent and reproducible assessment of sampling methods, data analysis, and response rates. To further refine the evaluation, a customised 3-point global assessment will be applied, scoring studies according to sample size adequacy, reproducibility, clarity of methodology, appropriateness of SMI diagnostic criteria and risk factor evaluation, including the depth of multivariate analysis. Data synthesis and statistical analysis Statistical synthesis will be performed using the R environment, using the meta and metafor packages for quantitative data pooling21 to estimate the pooled prevalence. While this updated systematic review replicates the structural methodology, search strategy and inclusion framework of the original 2021 meta-analysis, the statistical synthesis has been modernised to align with current epidemiological best practices. Specifically, due to expected clinical and methodological diversity across settings, statistical pooling of prevalence estimates will be conducted using a Generalised Linear Mixed Model (GLMM) with a logit transformation. This analytical approach was explicitly selected over the traditional DerSimonian-Laird random-effects model because GLMM is methodologically superior for pooling extreme proportions and does not require artificial continuity corrections for zero-event studies. This approach will ensure greater methodological credibility when handling the substantial heterogeneity commonly observed in observational prevalence meta-analyses. Heterogeneity will be assessed using the I2 statistic, where I2>50% indicates substantial heterogeneity. If data permit, subgroup analyses will be performed based on specific SMI diagnosis, geographic region and clinical setting (inpatient vs outpatient). Publication bias will be assessed using a funnel plot and Egger’s test if more than 10 studies are available. Amendments Any future necessary modifications to this study, for example, modifications to eligibility criteria, outcomes or analysis methods, will be substantiated in a dated amendment log. Each entry will include the date of the change, a description of the modification and a clear rationale. These changes will also be updated in the PROSPERO registry to maintain transparency and avoid reporting bias. Ethical considerations Formal ethical clearance is not required for this study, as it relies entirely on the synthesis of secondary data from published articles. The study will not involve interaction with human participants or the collection of identifiable individual-level data, thereby maintaining confidentiality and anonymity throughout the review. All primary studies included in this review will be expected to have been conducted following appropriate ethical approval and informed consent procedures, where applicable. The findings will be reported according to PRISMA 2020 guidelines to ensure transparency, integrity and the ethical dissemination of data concerning this vulnerable population. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. prepub: Prepublication history for this paper is available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-119668). Patient consent for publication: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. References